Proyectos de ley › 88.ª Asamblea General
Relating to the coverage of direct-acting antiviral drugs for Medicaid beneficiaries living with a chronic hepatitis C virus infection
Temas:Health careMedicaid
Dónde está ahora
- Hecho: Presentado15 de enero de 2019
- Hecho: Subcomité17 de enero de 2019
- Se detuvo: Comité del SenadoMurió al terminar la Asamblea General
- Sigue: Lo aprueba el Senado
- Sigue: Comité de la Cámara
- Sigue: Lo aprueba la Cámara
- Sigue: A gobernador(a)
- Sigue: Firmado como ley
Murió al terminar la sesión La sesión de 2020 terminó el 14 de junio de 2020, la última sesión ordinaria de la Asamblea General. Los proyectos que no pasaron por ambas cámaras murieron. ¿Qué es el embudo (funnel)?
Qué contiene
La explicación oficial está en inglés; todavía no hay resumen en palabras sencillas.
This bill relates to coverage of direct-acting antivrial drugs for a chronic hepatitis C virus (HCV) infection under the Medicaid programs. The bill requires the department of human services (DHS) to adopt rules pursuant to Code chapter 17A, amend all Medicaid managed care contracts, and submit any Medicaid state plan amendments to the centers for Medicare and Medicaid services of the United States department of health and human services (CMS) for approval, as necessary, to require that direct-acting antiviral drugs that are approved by the United States food and drug administration (FDA) for the treatment of chronic HCV-infected patients as a medically accepted indication are a covered outpatient drug under the Medicaid program, and shall be covered consistently for Medicaid beneficiaries under both the fee-for-service and managed care methodologies in accordance with the Medicaid state plan.
Lea la explicación completa
The bill requires that the rules adopted, and state plan amendment submitted, shall comply with all of the following requirements: 1. 2. 3. 4. If utilization controls are provided, such utilization controls shall ensure that appropriate access to the covered drugs is consistent with federal regulations, and specifically must ensure that the drugs are provided in a manner that is sufficient in amount, duration, and scope to reasonably achieve the purpose for which the drugs are furnished and are not arbitrarily denied or reduced in amount, duration, or scope solely because of the diagnosis, type of illness, or condition of the beneficiary. The bill also requires DHS to implement programming to provide patients who are undergoing and who have completed direct-acting antiviral HCV drug treatment with supportive care and surveillance to enhance their adherence to regimens and increase success rates, and to collaborate with the department of public health, bureau of HIV, STD, and hepatitis, to provide surveillance and determine the return on investment, benefits, and outcomes resulting from the provision of treatment to all chronic HCV-infected Medicaid beneficiaries, including due to averting new infections.
Senate subcommittee
Named January 17, 2019. It hasn’t reported yet.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Cabildeo
5 a favor · 0 en contra · 11 indecisos · Quiénes →